Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C. Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP). [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2014 Authors' conclusions Since October 1, 2013, following the implementation of an Institut national d'excellence en santé et en services sociaux (INESSS) recommendation, the total cost of reimbursing proton pump inhibitors (PPIs) has decreased significantly for the public prescription drug insurance plan, from a monthly average of $16.5 million in January 2012 to $8.9 million in March 2014. This is according to Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP), a follow-up report to the March 2013 public notice, which recommended to the Minister that he give preference to scenarios for reimbursing three or four generic PPIs based on the application of a measure referred to as the maximum payable price (MPP). Indexing Status Subject indexing assigned by CRD MeSH Drug Costs; Health Benefit Plans, Employee; Proton Pump Inhibitors; Proton Pumpss Country of organisation Canada English summary An English language summary is available. Address for correspondence Institut national d'excellence en santé et en services sociaux (INESSS), 1195 avenue Lavigerie, bureau 60 Québec (Québec) Canada, G1V 4N3
Email: inesss@inesss.qc.ca AccessionNumber 32014001081 Date abstract record published 17/09/2014 |